iMedicare expands to 500 pharmacies
NEW YORK — A patient-engagement and Medicare decision-making platform is now available in 500 pharmacies across the country.
iMedicare said the growth of the platform would help thousands of seniors enroll in affordable health insurance and prescription drug coverage by enabling pharmacists to help them shop for Medicare insurance plans, automatically integrating their prescription medications in one mobile system.
iMedicare works with major pharmacy software systems like Rx30, QS/1, Computer-Rx and others.
"Before iMedicare, choosing Medicare insurance was extremely difficult because it required manually inputting all of patients’ current medications," iMedicare CEO Flaviu Simihaian said. "Now, iMedicare has the ability to securely import the patients’ information in a matter of seconds."
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.
Prince Lionheart launches new toilet trainers
NEW YORK — Prince Lionheart is launching a new line of toilet trainers for small children, the company said Wednesday.
The weePOD trainer will be available starting next month at Target stores for $27.99 and comes in a variety of colors. It includes a slip-resistant ring that keeps the trainer in place and provides handles for stability and support, as well as a hanging loop for easy storage, and a design that makes it easy to clean.
The pottyPOD Basix is designed to be aesthetically pleasing to adults’ eyes and to fit with other bathroom decor, in addition to being light and small with a slip-resistant base. The product is available for $16.99 from Diapers.com.
Aptalis Pharma launches H. pylori treatment
BRIDGEWATER, N.J. — Aptalis Pharma has launched its 10-day drug therapy for treating a gastrointestinal bacterial infection and ulcer condition, the company said.
Aptalis announced the launch of Pylera 10 Day Therapy PAK (bismuth subcitrate potassium; metronidazole; tetracycline hydrochloride). The drug is approved for use in combination with the proton-pump inhibitor omeprazole in patients with Helicobacter pylori infection and duodenal ulcer disease that is either active or has a history of occurring within the past five years, for eradicating H. pylori.
Aptalis called Pylera the only branded treatment option for the condition that does not contain the macrolide antibiotic clarithromycin. According to one study, 92% of patients who had a strain of H. pylori resistant to clarithromycin had been treated with a macrolide antibiotic in the past 10 years.
"Almost 20 years after the establishment of clarithromycin-based triple therapy for the eradication of Helicobacter pylori, eradication rates are declining with this therapy, due to increasing rates of clarithromycin-resistant H. pylori," Aptalis president and CEO Frank Verwiel said. "Given this, it is important for physicians and patients to have a convenient non-macrolide treatment option like Pylera for H. pylori in the 10 Day Therapy PAK."